Samuel Jacob1, Justin H Nguyen2, Magdy M El-Sayed Ahmed3, Ian A Makey3, Osama K Haddad4, Mathew Thomas3,2, Basar Sareyyupoglu3, Si M Pham3, Kevin P Landolfo3,2. 1. Department of Cardiothoracic Surgery, Mayo Clinic, 4500 San Pablo Rd, Jacksonville, Florida, 32224, USA. Jacob.Samuel@mayo.edu. 2. Division of Transplant Surgery, Mayo Clinic, Jacksonville, Florida, USA. 3. Department of Cardiothoracic Surgery, Mayo Clinic, 4500 San Pablo Rd, Jacksonville, Florida, 32224, USA. 4. Mayo Clinic School of Graduate Medical Education, Mayo Clinic College of Medicine and Science, Jacksonville, Florida, USA.
Abstract
OBJECTIVE: Morbidity and mortality rates associated with liver transplant are high for patients with concomitant heart disease. Traditionally, such cases were considered contraindications for transplant. The objective of our study was to assess the outcome of combined surgical approaches. METHODS: A prospectively maintained database was analyzed of patients undergoing cardiac surgery and liver transplant at our institution. Twelve identified patients underwent combined cardiac operation and liver transplant. A control group was created (n = 24) with the same selection criteria. RESULTS: Median patient age was 64.94 years in the combined group vs 63.80 in the control, and in both groups, 58% were male. Left ventricular ejection fraction (0.60), body mass index (30.1), and median (range) score of the Model for End-stage Liver Disease (18 [9-33]) were the same in both groups. The cardiac operations combined with liver transplant were coronary artery bypass grafting, valve replacement procedures, and ascending thoracic aortic aneurysm repair. Piggyback liver transplant was performed for all patients. Survival periods of 1, 5, and 10 years for control vs combined cases were 90 vs 62%, 79 vs 55%, and 70 vs 45%, respectively (P = 0.03). CONCLUSION: Concomitant cardiac procedure and liver transplant is a valid treatment option and should be considered with risk stratification criteria of the patient with end-stage liver disease and cardiac surgical pathologic characteristics.
OBJECTIVE: Morbidity and mortality rates associated with liver transplant are high for patients with concomitant heart disease. Traditionally, such cases were considered contraindications for transplant. The objective of our study was to assess the outcome of combined surgical approaches. METHODS: A prospectively maintained database was analyzed of patients undergoing cardiac surgery and liver transplant at our institution. Twelve identified patients underwent combined cardiac operation and liver transplant. A control group was created (n = 24) with the same selection criteria. RESULTS: Median patient age was 64.94 years in the combined group vs 63.80 in the control, and in both groups, 58% were male. Left ventricular ejection fraction (0.60), body mass index (30.1), and median (range) score of the Model for End-stage Liver Disease (18 [9-33]) were the same in both groups. The cardiac operations combined with liver transplant were coronary artery bypass grafting, valve replacement procedures, and ascending thoracic aortic aneurysm repair. Piggyback liver transplant was performed for all patients. Survival periods of 1, 5, and 10 years for control vs combined cases were 90 vs 62%, 79 vs 55%, and 70 vs 45%, respectively (P = 0.03). CONCLUSION: Concomitant cardiac procedure and liver transplant is a valid treatment option and should be considered with risk stratification criteria of the patient with end-stage liver disease and cardiac surgical pathologic characteristics.
Authors: D M Manas; D R Roberts; D W Heaviside; S Chaudhry; K Tocewicz; M Hudson; P Bayly; M Thick; J Dark; O F James Journal: Clin Transplant Date: 1996-06 Impact factor: 2.863
Authors: D E Eckhoff; L Frenette; M T Sellers; B M McGuire; J L Contreras; J S Bynon; D C McGiffin Journal: Liver Transpl Date: 2001-01 Impact factor: 5.799
Authors: J J Morris; C L Hellman; B J Gawey; M A Ramsay; T R Valek; T C Gunning; T H Swygert; L Shore-Lesserson; F Lalehzarian; K L Brayman Journal: J Cardiothorac Vasc Anesth Date: 1995-06 Impact factor: 2.628
Authors: David Axelrod; Alan Koffron; Andre Dewolf; Alfred Baker; John Fryer; Talia Baker; James Frederiksen; Keith Horvath; Micheal Abecassis Journal: Liver Transpl Date: 2004-11 Impact factor: 5.799
Authors: Christopher C DeStephano; Barry A Harrison; Monica Mordecai; Claudia C Crawford; Timothy S J Shine; Winston R Hewitt; Lawrence R McBride; Michael J Murray Journal: J Cardiothorac Vasc Anesth Date: 2009-12-29 Impact factor: 2.628